Group's focus at the moment is the GeneRISK study. Dr. Widén worked with Professor Samuli Ripatti to set up the study in 2015 and recruit a cohort of around 7,300+ people from southern Finland. The cohort is unique as the participants consented to receive personal cardio-vascular disease risk information back from the study. The cohorts’ risk information was interpreted and communicated using an interactive web tool developed for this purpose, called KardioKompassi. GeneRISK as a study is still ongoing. and the first follow-up round has been completed.